© 2024 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Grace Halsey
Articles
Dupilumab, Ensifentrine Added to 2025 GOLD Guidelines for COPD: Expert Parses Recommendations
November 21, 2024
Professor MeiLan Han, MD, MS, details inclusion of the 2 new medications and how the additions reflect a focus on disease heterogeneity and precision medicine in in COPD.
More than Half of US Adults May Be Eligible for Semaglutide Therapy, Accordng to New Estimates
November 21, 2024
Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.
Antivirals for Influenza Underutilized Among Vulnerable Children, Adolescents
November 20, 2024
Analysis of surveillance data revealed a decline in use of antiviral medications for children hospitalized with influenza and prevalent underprescribing in outpatient settings.
Treatment for Agitation in Alzheimer Dementia: Pipeline Preview with George Grossberg, MD
November 20, 2024
"It's a very rich pipeline because [agitation] is a very common and very debilitating symptom in Alzheimer's disease," Grossberg observed.
Exercise of Any Level Linked to Reduced All-Cause Mortality in Individuals with Dementia
November 19, 2024
Physical activity of any level before and after a diagnosis of dementia was associated with at least a 20% lower risk for all-cause mortality across dementia subtypes.
2025 GOLD Report for COPD: MeiLan Han, MD, MS, Discusses Addition of Dupilumab, Ensifentrine
November 19, 2024
The 2 newly approved COPD therapies have been added to the GOLD guidelines section on follow-up therapy, expanding clinical options for specific patient types.
Awareness of Lung Cancer Screening Extremely Low Among Those at Highest Risk in the US: New Data
November 18, 2024
Among current smokers, 71% had never spoken a clinician about screening and among those who had quit, 75% had never had a conversation.
Intensive SBP Reduction Below 120 mm Hg Reduces MACE in Adults with Type 2 Diabetes
November 18, 2024
AHA 2024. Findings from the BPROAD trial help fill a gap left by similar studies on the ideal target SBP for adults with type 2 diabetes, said study authors.
Agitation in Alzheimer Disease and Antipsychotics Used Off-Label are Not Meant for Each Other
November 18, 2024
Antipsychotic medications are still used to treat potentially harmful acute agitation, George Grossberg, MD, explains, even though the adverse effects are well known.
European Medicines Agency Reverses Opinion on Lecanemab for Alzheimer Disease But Limits Eligible Population
November 15, 2024
The EMA recommendation excludes from treatment adults who are homozygous for the ApoE ε4 gene, a decision that the US Alzheimer's Association does not support, said the president/CEO.